In a 2023 framework, the World Health Organization (WHO) defined meaningful engagement as the respectful, dignified, and equitable inclusion of individuals with lived experience, following
With over 30 million individuals in the United States alone affected by 7,000 rare diseases,1 it is crucial to provide these patients with timely access to diagnosis and prompt t
Donovan Quill, AscellaHealth’s Executive Vice President of Growth and Strategy, describes the unique challenges associated with bringing new specialty and rare disease pharmaceutical produc
Industry stakeholders have moved beyond considering patients as clinical trial “subjects”, and instead recognise the tremendous value of viewing those most impacted by a disease as partners
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.